Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

By V. Fowler, H. Boucher, G. Corey, E. Abrutyn, A. Karchmer, M. Rupp, D. Levine, Henry F. Chambers, F. Tally, G. Vigliani and 16 more. New England Journal of Medicine, 2006

1,346 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Surgery

View Paper: https://www.semanticscholar.org/paper/addb68898af31a21c382a93f6760f375b2257cee

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Robert S. Daum

In Infectious Diseases

1. D. Levine
2. Robert S. Daum
3. S. Cosgrove
4. Henry F. Chambers
5. B. Lomaestro

In Surgery

1. S. Cosgrove

Citations in the corpus

• Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. (2011, background): “In a randomized trial, it was noninferior to initial low-dose gentamicin plus either vancomycin or an antistaphylococcal penicillin [49].”
• Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin (2008, background): “aureus bacteremia and infective endocarditis in its phase III clinical study (3).”
• GUIDELINES ON THE PREVENTION, DIAGNOSIS, AND TREATMENT OF INFECTIVE ENDOCARDITIS (NEW VERSION 2009) (2010, neutral): “Importantly, daptomycin needs to be administered in appropriate doses to avoid further resistance.(139,141) Other choices include newer b-lactams with relatively good PBP2A affinity, quinupristin–dalfopristin with or without b-lactams,(142,143) b-lactams plus oxazolidinones,(144) and b-lactams plus ”